Manager, IT and Cybersecurity
The Manager, IT & Cybersecurity will lead day-to-day corporate IT operations and cybersecurity execution, ensuring reliable, secure, and scalable technology services for the business. Reporting to the CFO this role manages operational priorities, drives continuous improvement, and partners across functions to align technology support with organizational needs.
This individual will work closely with the Managed Service Provider (MSP), oversee end‑user computing tools including M365, laptops, AV systems, and security infrastructure, and serve as a trusted partner to teams across Lexeo. The ideal candidate thrives in a fast‑paced, growing biotechnology environment and is equally comfortable troubleshooting immediate issues and implementing process improvements, including the responsible use of AI to optimize ticket triage/knowledge management and accelerate issue resolution, that support future growth.
The Manager, IT & Cybersecurity will lead day-to-day corporate IT operations and cybersecurity execution, ensuring reliable, secure, and scalable technology services for the business. Reporting to the CFO this role manages operational priorities, drives continuous improvement, and partners across functions to align technology support with organizational needs.
This individual will work closely with the Managed Service Provider (MSP), oversee end‑user computing tools including M365, laptops, AV systems, and security infrastructure, and serve as a trusted partner to teams across Lexeo. The ideal candidate thrives in a fast‑paced, growing biotechnology environment and is equally comfortable troubleshooting immediate issues and implementing process improvements, including the responsible use of AI to optimize ticket triage/knowledge management and accelerate issue resolution, that support future growth.
About Lexeo
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.
Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.